Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

Although there was no difference in the primary outcome in the overall population, observations in a subgroup of patients with early systemic inflammation suggest that trimodulin may have potential in this setting that warrants further investigation. ESSCOVID WAS REGISTERED PROSPECTIVELY AT CLINICALTRIALS.GOV ON OCTOBER 6, 2020.: NCT04576728.

Authors

Institutions

Publication Details

Journal
European journal of medical research
Published
2024-08-13
DOI
https://doi.org/10.1186/s40001-024-02008-x
Citations
5
Primary Topic
COVID-19 Clinical Research Studies
Type
article
Field-Weighted Citation Impact
1.56

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

Markus Ruehle, Javier Carbone, И. Г. Гордеев, Sergey Nikolaevich Avdeev et al.
5 citations
European journal of medical research
COVID-19 Clinical Research Studies
1.56
article

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

Markus Ruehle, Javier Carbone, И. Г. Гордеев, Sergey Nikolaevich Avdeev, Muriel Fartoukh, Alexander Staus, Claudio Stadnik, Guillaume Thiéry, Patrick Langohr, Iris Bobenhausen, Thomas Häder, Valéria Cristina Resende Aguiar, Д. Н. Проценко, Alina Agafina, Corina C. Heinz, Rita Pellegrini, Sabrina Weißmüller, Maria Rossovskaya, Miquel Ferrer, Antoní Torres, Andrea Wartenburg-Demand, Jean-François Timsit, Ludhmila Abrahão Hajjar, Jörg Schüttrumpf
article en
5 citations

Abstract

Although there was no difference in the primary outcome in the overall population, observations in a subgroup of patients with early systemic inflammation suggest that trimodulin may have potential in this setting that warrants further investigation. ESSCOVID WAS REGISTERED PROSPECTIVELY AT CLINICALTRIALS.GOV ON OCTOBER 6, 2020.: NCT04576728.

European journal of medical researchVol. 29(1)
Université Claude Bernard Lyon 1 (FR), Sechenov University (RU), Hospital General Universitario Gregorio Marañón (ES), Sorbonne Université (FR), Assistance Publique – Hôpitaux de Paris (FR), Biotest (Germany) (DE), City Hospital No. 40 (RU), Institute Cancer De La Loire Lucien Neuwirth (FR), Hospital Clínic de Barcelona (ES), Santa Casa de Misericórdia de Marília (BR), Grifols (Spain) (ES), City Clinical Hospital (RU), Hôpital Bichat-Claude-Bernard (FR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR), Centre Hospitalier Universitaire de Saint-Étienne (FR), Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES), Hôpital Tenon (FR), Universitat de Barcelona (ES)
Assistance publique-Hôpitaux de Paris, I.M. Sechenov First Moscow State Medical University, Sorbonne Université
Good health and well-being
Openalex Percentile: Top 17%
COVID-19 Clinical Research Studies
1.56
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.